2025
A Retrospective Analysis of the Impact of Electroconvulsive Therapy on Anxiety Symptoms in Patients With Treatment-Resistant Depression.
Laszcz J, Wang C, Riva-Posse P, Kim J, Tsygankova V, Mandell A, Rice H, Hermida A, Kitay B, Crowell A, McDonald W, Hershenberg R. A Retrospective Analysis of the Impact of Electroconvulsive Therapy on Anxiety Symptoms in Patients With Treatment-Resistant Depression. Journal Of Ect 2025 PMID: 39853314, DOI: 10.1097/yct.0000000000001113.Peer-Reviewed Original ResearchTreatment-resistant depressionTreatment-resistant depressed patientsElectroconvulsive therapySymptoms of depressionSymptoms of anxietyAnxiety symptomsDepressive symptomsAcute course of ECTGeneralized Anxiety Disorder 7 scalePredictors of antidepressant responseImprovement of anxiety symptomsImpact of electroconvulsive therapyCourse of ECTImprove symptoms of anxietyHigher symptoms of anxietyBeck Depression Inventory IIAnxiety symptom severityNaturalistic outpatient settingAcute ECT courseHigher levels of anxietyElectroconvulsive therapy treatmentsLevels of anxietyTrajectory of improvementAntidepressant responseAnxious symptoms
2024
Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses
Fogaça M, Daher F, Picciotto M. Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses. Neuropsychopharmacology 2024, 50: 673-684. PMID: 39390105, PMCID: PMC11845475, DOI: 10.1038/s41386-024-02002-1.Peer-Reviewed Original ResearchNovelty suppressed feeding testMedial prefrontal cortexSucrose splash testEffects of ketamineAntidepressant-like responseMajor depressive disorderGABAergic activityGABA interneuronsGlutamatergic activityGABA neuronsSustained antidepressant effectsGABA neuron activityLow dose of ketamineAdministration of ketamineDose of ketamineAntidepressant responseAntidepressant developmentSplash testAntidepressant effectsPrefrontal cortexDepressive disorderChemogenetic inhibitionBehavioral actionsAssociated with disruptionGABA functionNovel multi-modal methodology to investigate placebo response in major depressive disorder
Cusin C, Dillon D, Belleau E, Normandin M, Petibon Y, El-Fakri G, Dhaynaut M, Hooker J, Kaptchuk T, McKee M, Hayden E, Meyer A, Jahan A, Origlio J, Ang Y, Brunner D, Kang M, Long Y, Fava M, Pizzagalli D. Novel multi-modal methodology to investigate placebo response in major depressive disorder. Journal Of Affective Disorders 2024, 368: 1-7. PMID: 39233242, DOI: 10.1016/j.jad.2024.08.226.Peer-Reviewed Original ResearchPlacebo responseDepressive disorderRates of placebo responseMesocorticolimbic dopaminergic pathwayExpectation of rewardAntidepressant responseMesolimbic systemReward circuitryNeurobiological underpinningsNeurobiological mechanismsDopaminergic activityDopaminergic systemPlacebo respondersSymptom reductionDopaminergic pathwaysMulti-modal methodologyPlacebo phenomenonPsychological constructsTreatment developmentMDDPlacebo-ControlledClinical trialsDouble-blindRewardDesigning Clinical TrialsEarly-treatment cerebral blood flow change as a predictive biomarker of antidepressant treatment response: evidence from the EMBARC clinical trial.
Dang Y, Lu B, Vanderwal T, Castellanos F, Yan C. Early-treatment cerebral blood flow change as a predictive biomarker of antidepressant treatment response: evidence from the EMBARC clinical trial. Psychological Medicine 2024, 54: 3053-3062. PMID: 38720516, DOI: 10.1017/s0033291724001156.Peer-Reviewed Original ResearchMajor depressive disorderBrain regionsTreatment of Major Depressive DisorderHamilton Depression Rating Scale scoresBiomarkers of antidepressant treatment responseCerebral blood flowBiosignatures of Antidepressant ResponseDepression Rating Scale scoresSerotonin reuptake inhibitor treatmentAntidepressant treatment responseResponse to antidepressantsTreatment responseRating Scale scoresBiomarkers of treatment responseAssociated with increased cerebral perfusionEstablishing ModeratorsAntidepressant responseAntidepressant effectsDepressive disorderTemporal cortexNeural biomarkersPostcentral regionsCerebral blood flow changesWhole-brainDisabling illnessExploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 73-79. PMID: 38170185, PMCID: PMC11262580, DOI: 10.1089/cap.2023.0047.Peer-Reviewed Original ResearchDepression symptom improvementTreatment-resistant depressionChildren's Depression Rating ScaleReuptake inhibitor medicationsDepression Rating ScaleSymptom improvementAntidepressant responseInhibitor medicationKetamine responseAdolescent treatment-resistant depressionRapid-acting antidepressant agentsSelective serotonin reuptake inhibitor medicationsSerotonin reuptake inhibitor medicationsKetamine’s antidepressant responseCurrent depressive episodeSevere depressive symptomsGreater symptom improvementAttention-deficit/hyperactivity disorder diagnosisFuture therapeutic useAntidepressant medicationMedication trialsCrossover trialAntidepressant agentsClinical variablesDepressive episode
2023
Placebo’s role in the rapid antidepressant effect
Sanacora G, Colloca L. Placebo’s role in the rapid antidepressant effect. Nature Mental Health 2023, 1: 820-821. DOI: 10.1038/s44220-023-00141-w.Peer-Reviewed Original ResearchRandomized placebo-controlled studyPlacebo-controlled studyRapid antidepressant effectsRapid antidepressant responseRapid antidepressant actionsStudy arm assignmentAntidepressant actionAntidepressant effectsAntidepressant responseSurgical anesthesiaTreatment assignmentHigh ratePlaceboAnesthesiaKetamineThe Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2022
Replication of distinct trajectories of antidepressant response to intravenous ketamine
O'Brien B, Lee J, Kim S, Nandra G, Pannu P, Swann A, Murphy N, Tamman A, Amarneh D, Lijffijt M, Averill L, Mathew S. Replication of distinct trajectories of antidepressant response to intravenous ketamine. Journal Of Affective Disorders 2022, 321: 140-146. PMID: 36302492, DOI: 10.1016/j.jad.2022.10.031.Peer-Reviewed Original ResearchConceptsMajor depressive disorderKetamine infusionTreatment courseSevere depressionGroup of patientsIntravenous ketamine infusionOutpatient community clinicClinical trial samplesHigh depression groupIntravenous ketamineKetamine treatmentTreatment visitsAntidepressant responsePrior medicationMean ageCommunity clinicsDepressed patientsDepressive disorderModerate depressionRetrospective analysisInduction courseDepression groupDepressive symptomsPatientsNaturalistic sample
2021
Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population
Wang Y, Li S, Niu L, Ma Y, Qiu Y, Li S, Guobule N, Cao H, Li J. Polymorphisms of COMT and CREB1 are associated with treatment-resistant depression in a Chinese Han population. Journal Of Neural Transmission 2021, 129: 85-93. PMID: 34767111, DOI: 10.1007/s00702-021-02415-y.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionHamilton Depression Rating Scale-17Catechol-O-methyltransferaseCyclic AMP response element binding proteinRisk of treatment-resistant depressionPathophysiology of treatment-resistant depressionCREB1 geneAssociated with treatment-resistant depressionAssociated with antidepressant responseTreatment-resistant depressed patientsCatechol-O-methyltransferase rs4680Polymorphism of catechol-O-methyltransferaseCatechol-O-methyltransferase geneHDRS total scoreSymptoms of MDDNon-TRD groupAntidepressant responseAMP response element binding proteinDepressive disorderCREB1 polymorphismsDepressive symptomsTotal scoreSingle nucleotide polymorphismsGene-gene interaction effectsElement-binding proteinInterrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness
Luykx J, Loef D, Lin B, van Diermen L, Nuninga J, van Exel E, Oudega M, Rhebergen D, Schouws S, van Eijndhoven P, Verwijk E, Schrijvers D, Birkenhager T, Ryan K, Arts B, van Bronswijk S, Kenis G, Schurgers G, Baune B, Arns M, van Dellen E, Somers M, Sommer I, Boks M, Gülöksüz S, McLoughlin D, Dols A, Rutten B. Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry 2021, 91: 531-539. PMID: 34955169, DOI: 10.1016/j.biopsych.2021.10.013.Peer-Reviewed Original ResearchConceptsMajor depressive episodeHamilton Depression Rating Scale scoresDepression Rating Scale scoresRating Scale scoresPolygenic risk scoresPRS-SCZECT outcomeElectroconvulsive therapyScale scoreSevere major depressive episodeUnipolar major depressive episodeMajor depressive disorderSecondary outcomesAntidepressant responseECT treatmentDepressive episodeSubgroup analysisECT effectivenessPsychotic featuresDepressive disorderTreatment responseMAIN OUTCOMEEffective treatmentRisk scoreTherapy effectiveness
2020
Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses
Fogaça MV, Wu M, Li C, Li XY, Picciotto MR, Duman RS. Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses. Molecular Psychiatry 2020, 26: 3277-3291. PMID: 33070149, PMCID: PMC8052382, DOI: 10.1038/s41380-020-00916-y.Peer-Reviewed Original ResearchConceptsGABA interneuronsRapid antidepressant responseMajor depressive disorderAntidepressant effectsSynaptic plasticityAntidepressant responseRapid-acting antidepressantsAcetylcholine muscarinic receptor antagonistMuscarinic receptor antagonistCortical brain areasEffects of scopolamineAntidepressant actionChemogenetic inhibitionGABAergic interneuronsReceptor antagonistDepressive disorderMale miceInterneuron subtypesBrain areasInterneuronsMPFCTransient inhibitionAffective behaviorInhibitionSubtypesAP-1 controls the p11-dependent antidepressant response
Chottekalapanda R, Kalik S, Gresack J, Ayala A, Gao M, Wang W, Meller S, Aly A, Schaefer A, Greengard P. AP-1 controls the p11-dependent antidepressant response. Molecular Psychiatry 2020, 25: 1364-1381. PMID: 32439846, PMCID: PMC7303013, DOI: 10.1038/s41380-020-0767-8.Peer-Reviewed Original ResearchConceptsAP-1 functionSelective serotonin reuptake inhibitorsTranscriptional programsSpecific gene expression programsActivator protein-1 complexGene expression programsAntidepressant responseProtein-1 complexExpression programsMolecular networksC-JunAP-1PI3KExtracellular serotonin levelsSerotonin reuptake inhibitorsC-fosPrecise modeNeuronal plasticitySSRI actionAntidepressant effectsReuptake inhibitorsSSRI responseSerotonin levelsPrescribed drugsTherapeutic effectChapter 7 Neuroprotective roles of neurotrophic growth factors in mood disorders
Jiang C, Salton S. Chapter 7 Neuroprotective roles of neurotrophic growth factors in mood disorders. 2020, 145-172. DOI: 10.1016/b978-0-12-814037-6.00010-0.Peer-Reviewed Original ResearchBrain-derived neurotrophic factorNeurotrophic growth factorsMood disordersAntidepressant efficacyDepressive behaviorGrowth factorDepression-like behaviorAntidepressant actionAntidepressant responseDendritic lengthNeuroprotective roleSpine densityNeurotrophic factorNeurotrophin actionNeuronal cytoarchitectureAnimal modelsGene polymorphismsSynaptic plasticityProtein levelsDisordersReceptorsGenetic associationEfficacySpecific mechanismsCritical role
2019
Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression
Gryglewski G, Seiger R, Baldinger-Melich P, Unterholzner J, Spurny B, Vanicek T, Hahn A, Kasper S, Frey R, Lanzenberger R. Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression. The International Journal Of Neuropsychopharmacology 2019, 23: 20-25. PMID: 31740958, PMCID: PMC7064047, DOI: 10.1093/ijnp/pyz059.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyWhite matter microstructureRight unilateral electroconvulsive therapyDiffusivity metricsUnipolar treatment-resistant depressionPoor antidepressant responseEffective therapeutic optionUnilateral electroconvulsive therapyDiffusion tensor imaging sequencesElectrode placementTract-based spatial statisticsAntidepressant responseClinical outcomesTherapeutic optionsInternal capsuleRepeated-measures ANOVAPosterior limbTreatment responseMagnetic resonanceElectrical stimulationTherapyAxial diffusivityLeft hemisphereWarrants investigationN-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
Fogaça MV, Fukumoto K, Franklin T, Liu RJ, Duman CH, Vitolo OV, Duman RS. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 2019, 44: 2230-2238. PMID: 31454827, PMCID: PMC6898593, DOI: 10.1038/s41386-019-0501-x.Peer-Reviewed Original ResearchConceptsNovelty-suppressed feeding testMedial prefrontal cortexD-methadoneNMDA receptor antagonistAntidepressant actionPhospho-p70S6 kinaseReceptor antagonistN-methyl-D-aspartate receptorsNoncompetitive NMDA receptor antagonistTreatment-resistant patientsChronic unpredictable stressRapid antidepressant actionsDissociative side effectsPrimary cortical culturesMeasures of anhedoniaKetamine inducesAvailable antidepressantsTolerability profileAntidepressant effectsBDNF releaseAntidepressant responseResistant patientsFavorable safetySingle doseCortical culturesOptogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects
Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS. Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nature Communications 2019, 10: 223. PMID: 30644390, PMCID: PMC6333924, DOI: 10.1038/s41467-018-08168-9.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexAntidepressant effectsPyramidal cellsNovel rapid-acting antidepressantsRapid antidepressant effectsRapid-acting antidepressantsRapid antidepressant responseRapid antidepressant actionsAntidepressant actionAntidepressant responsePyramidal neuronsTherapeutic responseDRD2 dopamine receptorAnxiolytic responseDopamine receptorsSomatic stimulationTarget neuronsImpaired functionMajor subtypesOptogenetic stimulationParticular subtypeDownstream circuitryPrefrontal cortexKetamineNeurons
2018
VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine
Jiang C, Lin WJ, Labonté B, Tamminga CA, Turecki G, Nestler EJ, Russo SJ, Salton SR. VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. Neuropsychopharmacology 2018, 44: 971-981. PMID: 30504797, PMCID: PMC6462025, DOI: 10.1038/s41386-018-0277-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntidepressive AgentsBehavior, AnimalBrain-Derived Neurotrophic FactorDepressionDepressive Disorder, MajorDisease Models, AnimalDisease SusceptibilityFemaleHumansKetamineMaleMiceMice, 129 StrainMice, Inbred C57BLMice, TransgenicNerve Growth FactorsNeuropeptidesPeptidesPrefrontal CortexStress, PsychologicalConceptsChronic restraint stressMajor depressive disorderAntidepressant efficacyAntidepressant responseVentromedial prefrontal cortexPrefrontal cortexAntidepressant drug treatmentKetamine's antidepressant efficacyAntidepressant-like effectsDepression-related behaviorsBrodmann area 25Neuropeptide precursor VGFChannel-mediated Ca2Underlying molecular pathwaysTLQP-62Vgf knockdownVGF levelsBDNF expressionMDD patientsRestraint stressDepressive disorderFunctional deficitsDrug treatmentBehavioral deficitsNucleus accumbensThe neurotrophic and antidepressant actions of BDNF and VEGF require interactive signaling
Deyama S, Baing E, Kato T, Li X, Duman R. The neurotrophic and antidepressant actions of BDNF and VEGF require interactive signaling. Proceedings For Annual Meeting Of The Japanese Pharmacological Society 2018, WCP2018: po2-1-62. DOI: 10.1254/jpssuppl.wcp2018.0_po2-1-62.Peer-Reviewed Original ResearchBrain-derived neurotrophic factorVascular endothelial growth factorMedial prefrontal cortexAntidepressant actionAntidepressant effectsDendritic complexityNeurotrophic factorCortical neuronsPrimary cultured cortical neuronsNovelty-suppressed feeding testNeuronal vascular endothelial growth factorGrowth factorNeuron-specific deletionCultured cortical neuronsActivity-dependent releasePrimary cortical neuronsEndothelial growth factorIntra-mPFC infusionBDNF-TrkBBDNF receptorAntidepressant responseBDNF infusionSwim testVEGF infusionNeurotrophic responses
2017
VGF function in depression and antidepressant efficacy
Jiang C, Lin WJ, Sadahiro M, Labonté B, Menard C, Pfau ML, Tamminga CA, Turecki G, Nestler EJ, Russo SJ, Salton SR. VGF function in depression and antidepressant efficacy. Molecular Psychiatry 2017, 23: 1632-1642. PMID: 29158577, PMCID: PMC5962361, DOI: 10.1038/mp.2017.233.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsAntidepressive AgentsBrain-Derived Neurotrophic FactorDepressionDepressive DisorderDown-RegulationFemaleHippocampusHumansKetamineMaleMiceMice, Inbred C57BLMiddle AgedNerve Growth FactorsNeuronsNeuropeptidesNucleus AccumbensReceptors, AMPASex FactorsSignal TransductionStress, PsychologicalTOR Serine-Threonine KinasesUp-RegulationConceptsChronic social defeat stressDepression-like behaviorBrain-derived neurotrophic factorSocial defeat stressNucleus accumbensAntidepressant efficacyAntidepressant responseDefeat stressFloxed micePro-depressant effectsRapid antidepressant efficacyBDNF/TrkBIsoxazolepropionic acid (AMPA) receptorsWild-type miceDepressed human subjectsBDNF translationTLQP-62VGF levelsAAV-CreAntidepressant behaviorNeurotrophic factorSwim testDorsal hippocampusInhibitory interneuronsVGF expressionMetabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies
Esterlis I, Holmes SE, Sharma P, Krystal JH, DeLorenzo C. Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies. Biological Psychiatry 2017, 84: 95-105. PMID: 29100629, PMCID: PMC5858955, DOI: 10.1016/j.biopsych.2017.08.025.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPositron emission tomography studyEmission tomography studiesMGluR5 modulationAntidepressant responseStress disorderBipolar disorderStress-related psychiatric disordersTomography studyAntagonism of mGluR5Ketamine’s antidepressant responseSignificant side effectsPromising therapeutic targetReceptor imaging studiesPosttraumatic stress disorderMDD heterogeneityManic mood statesAntidepressant efficacyObsessive-compulsive disorderDepressive disorderSubtype 5Neurotransmitter systemsPsychiatric disordersReceptor 5Side effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply